skip to main content

H.R. 3523: End Price Gouging for Medications Act

The text of the bill below is as of Jun 26, 2019 (Introduced).


I

116th CONGRESS

1st Session

H. R. 3523

IN THE HOUSE OF REPRESENTATIVES

June 26, 2019

(for himself and Mr. Rooney of Florida) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, Veterans' Affairs, Oversight and Reform, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To require the Secretary of Health and Human Services to establish reference prices for prescription drugs for purposes of Federal health programs, and for other purposes.

1.

Short title

This Act may be cited as the End Price Gouging for Medications Act.

2.

Reference prices for prescription drugs

(a)

Reference prices

The Secretary of Health and Human Services (referred to in this section as the Secretary), in accordance with subsection (b), shall establish annual reference prices for each prescription drug. Notwithstanding any other provision of law, with respect to enrollees or beneficiaries in any of the Federal health programs described in subsection (c), the retail list price for a drug shall not exceed the reference price for such drug.

(b)

Criteria

(1)

In general

Each year, the Secretary shall establish the reference price for each prescription drug under subsection (a)—

(A)

by determining the median retail list price for the drug among the reference countries in which the drug is available, if drug pricing information is available for at least three of such countries; or

(B)

in the case of a drug for which drug pricing information or dosage equivalents are not available for at least three of the reference countries, by determining an appropriate price based on the Secretary’s determination of—

(i)

the added therapeutic effect of the drug;

(ii)

the value of the drug;

(iii)

patient access to the drug;

(iv)

the costs associated with researching and developing the drug; and

(v)

other factors, as the Secretary determines appropriate.

(2)

Reference countries

For purposes of paragraph (1), the reference countries are Japan, Germany, the United Kingdom, France, Italy, Canada, Australia, Spain, the Netherlands, Switzerland, and Sweden.

(c)

Federal health programs

The reference prices established under subsection (a) shall apply with respect to covered inpatient and outpatient drugs under—

(1)

the Medicare program under title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.);

(2)

a State Medicaid plan under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.);

(3)

the State Children's Health Insurance Program under title XXI of the Social Security Act (42 U.S.C. 1397aa et seq.);

(4)

the TRICARE program under chapter 55 of title 10, United States Code;

(5)

hospital care and medical services furnished by the Department of Veterans Affairs under chapters 17 and 18 of title 38, United States Code;

(6)

the Federal Employees Health Benefits Program established under chapter 89 of title 5, United States Code; and

(7)

any health program, service, function, activity, or facility funded, in whole or part, under the Indian Health Care Improvement Act (25 U.S.C. 1601 et seq.), including through direct or contract care provided under such Act or through a contract or compact under the Indian Self-Determination and Education Assistance Act (25 U.S.C. 5304 et seq.).

(d)

Applicability to other purchasers of drugs

Notwithstanding any other provision of law, a drug manufacturer shall offer prescription drugs at the reference price to all individuals, including individuals who are not insured and individuals who are covered under a group health plan or group or individual health insurance coverage. In the case of individuals covered by a group health plan or group or individual health insurance coverage, such requirement is met if the amount covered under such plan or coverage plus the cost-sharing amount does not exceed the reference price.

(e)

Enforcement

(1)

Civil penalty

A drug manufacturer who does not comply with the requirements of subsection (a) shall be subject to a civil penalty, for each year in which the violation occurs and with respect to each drug for which the violation occurs, in an amount equal to 5 times the difference between—

(A)

the total amount received by the manufacturer for sales of the drug under the Federal health programs under subsection (c) for the year; less

(B)

the total amount the manufacturer would have received for sales of the drug under such programs for the year if the manufacturer had complied with subsection (a).

(2)

Amounts collected

Each year, the Secretary of the Treasury shall transfer to the Director of the National Institutes of Health an amount equal to the amount collected in civil penalties under subsection (e) for the previous year. The Director of the National Institutes of Health shall use amounts so transferred for purposes of conducting drug research and development.

(f)

Applicability to brand and generic drugs

The reference price established under subsection (a) shall apply to drugs approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C. 262).